Recently, an increasing number of clinical trials have focused on evaluating anti‐tumor effect of PLK1 inhibitors in patients with relapsed or refractory cancers.[8, 18] However, the pharmacological mechanisms by which PLK1 inhibition revers chemoresistance remain unclear. Here, PLK1 is linked to cancer.